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Abstract: The aim of our study was to elucidate the possible involvement of COX-2 in the development and/or
progression of nonmelanocytic skin lesions. To evaluate the usefulness of that enzyme as a potential molecular
marker, we examined the intensity and spatial distribution of COX-2 expression in selected types of such tumors
using the same immunohistochemical procedure as in our earlier studies of melanocytic cancers. We examined
20 benign epithelial lesions, 11 precancerous lesions, 21 basal cell carcinomas (BCC), 14 squamous cell carcino-
mas (SCC) and eight fibromas. The levels of COX-2 expression detected in benign lesions and in normal skin
were comparable. Elevated expression of this protein may play a role in the development of SCC, as indicated by
strong immunostaining both in SCCs and precancerous lesions. Significantly stronger staining in SCCs com-
pared to BCCs may indicate a role of COX-2 in cancer malignancy and serve as an indicator useful for differen-
tial diagnostics of the two types of cancer. Strong staining in all skin layers of SCC may help in detecting cancer
cells infiltrating surrounding skin layers. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 381–388)
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Introduction
Cyclooxygenases play a key role in the biosynthesis
of prostaglandins [1, 2]. Two isoforms of COX have
been identified in human cells: COX-1 and COX-2,
each encoded by a different gene [3, 4]. Constitutive
expression of COX-1 has been found in cells in most
human tissues [1, 3] while COX-2 is normally ex-
pressed only by cells of a few organs such as the brain,
testes, trachea and kidney [5, 6]. COX-2 expression
may also be induced in endothelial and smooth mus-
cle cells and in fibroblasts after stimulation by growth
factors, cytokines, lipopolysaccharides and tumor pro-
moters [7, 8]. Many studies have demonstrated the
overexpression of COX-2 in cells of different human
tumors, mostly of epithelial origin like cancers of the
colon and rectum [9–13], breast [14, 15], stomach
[16, 17], lung [18], bladder [19–21], head and neck
[22–24], ovary [25, 26], cervix [27, 28], prostate [29]
and pancreas [30].
Human skin is composed of cells of different ori-
gin and thus the group of skin tumors is much differ-
entiated. Our studies have demonstrated that the
development and progression of human cutaneous
melanoma are accompanied by a clear increase of
COX-2 expression in melanocytes [31, 32]. It should
be noted that earlier data on COX-2 expression in
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human cutaneous melanocytic lesions was very incon-
sistent. Recently, we have demonstrated that immu-
nostaining with three different primary antibodies
yielded significantly different percentage fractions of
the COX-2 expressing melanocytes detected in indi-
vidual naevi and melanomas, while the staining of
normal skin was similar for all three antibodies [33].
Immunohistochemical studies of COX-2 expres-
sion in human cutaneous epithelial tumors and in
normal skin reported to date have yielded quite in-
consistent data. Leong et al. [34] found strong COX-2
expression in squamous cell carcinomas (SCC), while
the cells of basal cell carcinomas (BCC) displayed
a weak staining. The authors also detected the COX-2
expression of normal skin, but restricted to kerati-
nocytes of the granular and spinous layers. Vogt et al.
[35] were not able to detect the COX-2 protein in any
of 11 cases of BCC, but observed medium and/or
strong expression of the protein in nine of 17 cases of
SCC and weak staining in two of six keratoacantho-
mas (KA). The staining pattern observed for cells of
the normal skin was similar to that described by Le-
ong et al. [34]. In the study by Putti et al. [36], COX-2
expression was detected in 13 of 17 SCCs and eight
of 24 KAs. Kagoura et al. [37] examined 16 cases of
BCC for the presence of the COX-2 protein and ob-
tained immunostaining of six samples (two — strong,
four — weak). The same authors reported slightly
stronger COX-2 expression in ten of 13 cases of Bo-
wen’s disease (BD) and even stronger in 11 of 15
SCCs. In both types of the lesions, the percentage frac-
tions of COX-2 positive cells in individual lesions var-
ied significantly and metastases expressed COX-2 at
lower levels than primary SCC and BD. In normal
skin, the COX-2 expression was found only in differ-
entiated keratinocytes, similarly to observations of
Leong et al. [34] and Vogt et al. [35]. Nijsten et al.
[38] described comparable levels of COX-2 expres-
sion in SCCs and actinic keratoses (AK), stronger than
in BDs, while in normal skin they were able to detect
COX-2 in only two of 35 cases investigated with the
staining limited to cells of the granular layer. Inter-
estingly, several authors did not detect COX-2 expres-
sion in keratinocytes of granular and spinous layers
and instead reported the staining of cells within the
basal layer [39–43]. Müller-Decker et al. [39] observed
COX-2 staining of some cells of the epidermal basal
layer in only two of nine samples of normal skin. In
the same study, clear COX-2 expression was detect-
ed in all examined cases of AK, KA, SCC and in one
case described as skin cancer in situ. Weak expres-
sion of COX-2 was also demonstrated in six of eight
BCCs. COX-2 positive cells were present in SCCs in
all the skin layers, but the strongest expression was
found in the spinous layer of cancer in situ. Kim et al.
[40] were able to detect COX-2 expression in only
five of ten SCCs, four of ten cases of BD, five of ten
AKs and two of ten cases of porokeratosis. At the
same time the authors detected COX-2 in eight of
ten BCCs. Some of the COX-2 positive lesions dis-
played a strong staining: BD — 50%, AK — 20% and
BCC — 12.5% of positive cases. In normal skin,
a weak staining was found in the epidermal basal lay-
er in four of ten specimens. Finally, An et al. [41] did
not find any COX-2 expression in normal human skin
but the COX-2 positive cells were detected both within
the lesions and/or in stroma for ten of 11 SCCs, sev-
en of eight cases of BD, ten of 12 AKs and nine of 16
BCCs. Characteristically, the COX-2 positive cells of
BD and SCC were always present in epidermal layers
above the basal layer, while BCCs generally displayed
positive staining of stromal cells. Only in two cases of
BCC were the positive cells present both within the
lesions and the stroma.
In this study, we examined specimens of selected
types of nonmelanocytic cutaneous lesions (benign
and precancerous epithelial lesions, SCCs and BCCs)
for differences in both COX-2 expression levels and
spatial distributions of the COX-2 positive cells. Im-
munohistochemical detection of the COX-2 protein
was carried out using the procedure elaborated earli-
er for studies of melanocytic lesions of human skin.
Material and methods
Patient material. Formalin-fixed paraffin-embedded tissue
samples were obtained from pathology units of the Munic-
ipal and Regional Hospitals, Torun, Poland. The study was
carried out as part of a project approved by the Committee
of Scientific Research at the School of Medicine, Bydgoszcz,
Poland. The samples were characterized independently by
the hospital staff and by pathologists from the Department
of Tumor Pathology, Oncology Centre — Maria Sklodow-
ska-Curie Institute, Gliwice, Poland. The material included
20 benign epithelial lesions (verruca seborrhoica — 14, pap-
illoma — six), 11 precancerous lesions (AK — two, KA —
three, BD — six) and 35 malignant lesions (BCC — 21, SCC
— 14). The group of the BCCs included five superficial,
11 nodular, two adnexal, one cystic and two mixed (nodular
and infiltrating) types. The group of the SCCs could be strat-
ified according to the differentiation degree into six cases
of high, three of medium and one of low degree of differen-
tiation. Eight fibromas were also involved in the study.
Immunohistochemistry. The procedure of immunohis-
tochemical staining, elaborated and tested using samples of
normal human skin, was described in our earlier papers on
COX-2 detection in human cutaneous melanocytic lesions
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[31, 32]. Briefly, 3 μm sections were mounted on 3-amino-
propyltriethoxysilane (APES; Sigma-Aldrich, St. Louis, MI,
USA), dewaxed and rehydrated. The slides were then im-
mersed in 0.01M citrate buffer pH 6.0 and heated for 60
min at 90°C. Endogenous peroxidase was blocked by 30 min
incubation with 0.3% H2O2 (Sigma-Aldrich) and nonspe-
cific binding of antibodies was prevented by 30 min incuba-
tion with 1.5% normal rabbit serum (Vector Laboratories,
Burlingame, CA, USA). Finally, the slides were incubated
in a humid chamber at room temperature for 60 min with
primary goat polyclonal COX-2 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) in a dilution 1:100 v/v in
PBS pH 7.4. Immunocomplexes were visualized using the
peroxidase technique with Vectastain Elite ABC Kit (Vec-
tor Laboratories) according to the procedure supplied with
the kit, and stained using 0.05% 3.3’-diaminobenzidine
(DAB; Sigma-Aldrich) with 0.01% H2O2 (Sigma-Aldrich)
and 0.06% NiCl2 (Sigma-Aldrich). Owing to the inclusion
of NiCl2 the color of the reaction product changed from typ-
ical brown to blue to black [44, 45], making the precipitate
easier to detect against the background of melanin present
in some of the lesions investigated. Negative control sec-
tions were incubated with PBS pH 7.4 solution without pri-
mary antibody and did not display any reaction products.
Microscopic examination was done using a BX41 mi-
croscope (Olympus Optical Co., Tokyo, Japan) with white
light illumination. Digital images were acquired with a Col-
orView III camera (Soft Imaging System, Hanover, Ger-
many) and analySIS 3.2 software (Soft Imaging System).
Quantitative immunohistochemical scoring involved deter-
mination of percentage fractions of the COX-2 positive cells.
Cell counts were carried out for individual skin layers for three
fields of view at magnification × 1,000. Three regions were
analyzed for each section: the center and periphery of the le-
sion and adjacent normal skin. The intensity of immunostain-
ing of individual cells was also determined and classified as
weak (blue, +) or strong (dark blue to black, + +).
Statistical analysis. Data (percentage fractions of the pos-
itively stained cells) is presented as mean values ± stan-
dard deviations calculated for the central (c) and border
(b) regions of the lesions and for the adjacent normal skin.
Statistical significance of the data was assessed using Stu-
dent’s t-test with the standard p < 0.05 condition (Microsoft
Excel; Microsoft, Redmond, WA, USA).
Results
We investigated the intensity and spatial pattern of
the expression of COX-2 in 74 nonmelanocytic skin
lesions and in the adjacent normal skin. Immunore-
activity of the COX-2 protein showed cytoplasmic,
often perinuclear, staining in both tumor and normal
skin cells.
Normal skin adjacent to the lesions showed char-
acteristic pattern of positive staining of keratinocytes
of the spinous and granular layers. The staining in-
tensity increased towards the skin surface and was
slightly stronger in the granular layer than in the
spinous layer. No expression of COX-2 was observed
in the basal layer. COX-2 expression and the spatial
distribution of the COX-2 positive keratinocytes were
similar in normal skin surrounding skin lesions of dif-
ferent types i.e. benign, precancerous and malignant
(Figures 1, 2A).
The COX-2 expression in benign epithelial skin
lesions (verrucas and papillomas) was similar to that
in the normal skin (Figures 1, 2A, B, 3A). The stain-
ing pattern was the same for central and peripheral
regions of the lesions.
All three types of precancerous lesion (AK, KA
and BD) expressed COX-2 significantly more strong-
ly than the benign lesions, both in terms of percent-
age fractions of the COX-2 positive cells and of the
contribution of cells with a strong (+ +) staining (Fig-
ures 2C, 3B). Enhanced COX-2 expression was ob-
served in the spinous and granular layers of the epi-
dermis. Moreover, unlike the normal skin and benign
lesions, the precancerous lesions also showed stain-
ing of keratinocytes of the epidermal basal layer, al-
though the percentage fraction of the COX-2 posi-
tive cells was in this layer significantly lower compared
to the spinous layer (Figure 3C).
BCCs expressed COX-2 weakly at levels lower than
the benign epithelial lesions (pc = 0.02, pb = 0.01).
Percentage fractions of the COX-2 positive cells were
similar (within limits of standard deviations) in all the
histologic types of BCC investigated (Figure 3D). The
highest fractions of cells with positive staining were
Figure 1. Mean percentage fractions of cyclooxygenase-2
(COX-2) positive keratinocytes in normal skin adjacent to
benign, precancerous and malignant lesions. Dark-shaded
and light-shaded fields illustrate the contribution of cells
with heavy (+ +) and light (+) staining, respectively
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consistently found in the granular layer, slightly lower
in the spinous layer, and significantly lower in deep-
er layers of the skin. The COX-2 positive cells
present in the epidermal basal layer and in the der-




Figure 2. Immunoreactivity for cyclooxygenase-2 (COX-2) in: normal skin (A), verruca seborrhoica (B), AK (C),
BCC (D), SCC (E) and fibroma (F). Respective images illustrate areas of central regions of the lesions. Different layers
of the skin designated as follows: b — basal; g — granular; p — papillary; r — reticular; s — spinous; COX-2 positive cells
indicated by arrows; magnification × 200
also less often demonstrated strong (+ +) staining
(Figures 2D, 3E).
Unlike the BCCs, all the SCC lesions showed very
strong COX-2 expression, comparable to the expres-
sion detected in the precancerous lesions (pc = 0.3,
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Figure 3. Mean percentage fractions of cyclooxygenase-2
(COX-2) positive cells in different skin layers in benign
epithelial lesions (A) and in benign epithelial and precance-
rous lesions (B), in different skin layers in precancerous
lesions (C), in BCCs of different histologic types (D) and in
different skin layers in BCCs (E), in different skin layers in
SCCs (F), in SCCs versus BCCs (G), in SCCs of different
degree of differentiation (H) and in fibromas (I). Dark-
-shaded and light-shaded fields illustrate the contribution of
cells with heavy (+ +) and light (+) staining, respectively
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pb = 0.2; compare Figures 2C, E). The only excep-
tion was the slightly lower expression of COX-2 pro-
tein by the SCC cells present in the basal layer at pe-
ripheral regions of the lesions (Figure 3F). Both the
percentage fraction of COX-2 positive cells and the
frequency of such cells displaying strong (+ +) stain-
ing were higher in the SCC group than in the benign
lesions (pc = 2 · 10
–7, pb = 8 · 10
–7; Figures 2B, E) or in
the BCCs (Figures 2D, E, 3G) and the differences
were statistically significant. No differences were
found between SCCs of different grades of differen-
tiation (Figure 3H). Also the cancer cells present in
different skin layers showed similar levels and pat-
terns of COX-2 expression.
Fibromas expressed COX-2 at very low or unde-
tectable levels (Figures 2F, 3I). Normal skin surround-
ing fibromas showed a staining pattern similar to that
of normal skin adjacent to epithelial lesions.
Finally, there was no difference in the data obtained
for central and peripheral regions of the lesions.
Discussion
Despite 15 years of study, neither the role nor the
patterns of COX-2 expression in normal human skin
and cutaneous pathologic lesions have yet been fully
elucidated. Literature data on COX-2 expression in
normal skin varies from reports of nondetectable ex-
pression levels [41], to the expression observed only
in some cells of the granular and spinous layers of
the epidermis [34, 35, 37] or restricted exclusively to
the epidermal basal layer [39, 40, 42, 43]. Leong et al.
[34] described an association between differentiation
of human keratinocytes in vitro and expression of
COX-2. Well known possible sources of discrepan-
cies in the reported results may include differences
in antibodies used, preparation of the material from
fixation and embedding to antigen retrieval, etc.
In this work, and in our earlier studies of COX-2
in melanocytic cutaneous lesions and in adjacent skin
[31, 32], we have consistently observed in a large num-
ber of samples of normal human skin positive stain-
ing of keratinocytes of the granular and spinous lay-
ers. Our present study demonstrated that papillomas,
verrucas and normal skin express COX-2 at compa-
rable levels. Thus, development of these benign le-
sions is not associated with enhanced expression of
COX-2 by keratinocytes.
Fibroblasts of normal skin did not express COX-2
at a detectable level. On the other hand, fibromas
were characterized by very weak staining of fibro-
blasts. Adler et al. [46] also reported COX-2 expres-
sion in 19 of 20 fibromas; and in 75% of the cases, the
fraction of stained cells exceeded 34%.
Precancerous lesions investigated in this study
(AK, KA, BD) expressed COX-2 significantly more
strongly than the benign epithelial lesions. Interest-
ingly, elevated expression of the enzyme was observed
not only in the granular and spinous layers but also in
the basal layer which did not show any staining in the
normal skin and the benign lesions. Epidemiological
data indicates a strong relation between the presence
of AK and the development of SCC: 82.4% of such
skin cancers were found either within (26.7%) or close
to (55.7%) actinic keratoses [47]. The estimated ten-
-year risk of developing SCC against a background of
AK is 13–20% [48], while for KA the risk of progres-
sion to SCC is 3.6–13.9%, depending on the age group
[49]. In our study, the precancerous lesions and SCCs
expressed COX-2 at a similar level. Although some
authors have reported stronger COX-2 staining in
SCCs compared to KA [35, 36] more groups have
described similar (or only slightly higher) COX-2 ex-
pression in SCCs compared to precancerous lesions
like AK, KA and BD [37–41].
It is thus plausible that elevated COX-2 expres-
sion plays a role in the development of SCC. Such
a conclusion is further supported by the therapeutic
efficacy of diclofenac (COX-2 inhibitor) in the treat-
ment of AK [50].
BCCs examined in this work showed a weak ex-
pression of COX-2, comparable with, or lower than,
that observed for the benign epithelial lesions. Such
a result is in general agreement with earlier reports
of other groups which have described very low COX-2
expression in most BCCs (undetectable in others)
[39, 40] or undetectable COX-2 expression in the ma-
jority of cases with weak expression found only in
a small fraction of the lesions investigated [34, 35, 37, 41].
Taking into account the good reproducibility of our
results for a large number of samples of normal skin,
and the consistency of the results obtained for BCCs,
it seems reasonable to conclude that the reports of
undetectable COX-2 expression in smaller or larger
fractions of the BCCs examined in earlier studies re-
flected insufficient sensitivity of the COX-2 detection
rather than a lack of the protein in the BCC cells.
The SCCs investigated in this present work ex-
pressed COX-2 significantly more strongly than the
BCCs. A similar relation has been found in several
earlier studies [34, 35, 37, 39–41]. Differences in both
the level and pattern of  COX-2 expression by cells of
the two types of skin cancer may be due to the fact
that SCC originates from more differentiated cells and
COX-2 has been suggested to be involved in the dif-
ferentiation of keratinocytes [34]. Furthermore, the
observation that all the SCCs show a similarly en-
hanced expression of COX-2 independently of the
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differentiation degree may indicate a role of COX-2
in the development of SCC, but not necessarily in the
progression of the disease.
Strong staining of the SCC cells present in any of
the skin layers makes the COX-2 protein a molecular
marker useful for precise and sensitive detection of
the cancer cells in histopathologic specimens.
The staining pattern observed for SCCs is very
different from BCC staining, which is typically limit-
ed to a zone of differentiated skin cells with a very
weak staining of the cancer cells present in the basal
layer and dermis. The staining pattern of BCCs was
similar for all the histologic types of the lesions and
the expression level did not change even at stages of
local invasiveness.
In our earlier study [51], we also observed strong
expression of cyclin-dependent kinase 2 (CDK-2) of
the SCC cells across all the skin layers. Similarity of
the expression patterns of CDK-2 and COX-2 in SCCs
may indicate a role of elevated COX-2 expression in
the proliferation of cancer cells. Such a conclusion is
further supported by in vitro studies by Higashi et al.
[52] who found that inhibiting COX-2 expression
caused growth suppression of the SCC cells.
In conclusion, our study demonstrates that nei-
ther the development of benign epithelial skin lesions
and BCC, nor the local invasiveness of the latter, are
associated with enhanced COX-2 expression. An ele-
vated level of this enzyme seems to play a role in the
development of SCC. This is evidenced by strong
staining found both for the cancerous and precancer-
ous lesions. Significantly higher COX-2 expression in
SCC compared to BCC may be useful for differential
diagnostics of the two cancer types, while strong stain-
ing of the SCCs across all the skin layers may help in
detecting cancer cells in histopathologic examinations.
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